Keros Therapeutics' (KROS) Buy Rating Reiterated at HC Wainwright

Keros Therapeutics (NASDAQ:KROS - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright's price objective points to a potential upside of 300.80% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald downgraded Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. TD Cowen cut shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Truist Financial reduced their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a research report on Monday, December 23rd. Piper Sandler lowered their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Finally, Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.33.

Remove Ads

Keros Therapeutics Trading Down 2.9 %

KROS stock traded down $0.30 during trading on Tuesday, hitting $9.98. The company had a trading volume of 1,544,444 shares, compared to its average volume of 718,431. The company has a fifty day moving average price of $11.00 and a two-hundred day moving average price of $32.99. Keros Therapeutics has a fifty-two week low of $9.41 and a fifty-two week high of $72.37. The company has a market cap of $404.81 million, a P/E ratio of -1.92 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. On average, analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Braidwell LP grew its holdings in shares of Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after buying an additional 1,187,199 shares during the period. Point72 Asset Management L.P. lifted its holdings in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after acquiring an additional 577,220 shares in the last quarter. Lynx1 Capital Management LP bought a new position in Keros Therapeutics during the fourth quarter worth about $8,612,000. Millennium Management LLC grew its stake in Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after acquiring an additional 305,169 shares during the period. Finally, Integral Health Asset Management LLC increased its holdings in shares of Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company's stock worth $7,124,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.